Cinta Albacar
YOU?
Author Swipe
View article: A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials Open
Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome s…
View article: Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial Open
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast le…
View article: Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial Open
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). Objective: We assessed …
View article: Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients
Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients Open
Background: Altered lipid metabolism has been described in some types of cancer. To analyse in depth the metabolic modifications in breast cancer patients, advanced 1H-nuclear magnetic resonance was performed in these patients. The main ob…
View article: 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study Open
View article: Chemotherapy De-Escalation Using an <sup>18</sup>F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial
Chemotherapy De-Escalation Using an <sup>18</sup>F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial Open